Monitor the ASCO presentations for quantitative biodistribution and dosimetry data, which could de-risk the AKY-2519 program and influence future trial design. While no immediate commercial catalyst, positive data may support sentiment ahead of mid-2026 Phase 1b initiation.
Price Chart
Executive Summary
Aktis Oncology announced upcoming ASCO poster presentations showcasing clinical imaging and dosimetry data for AKY-2519, a B7-H3-targeted radiopharmaceutical, with Phase 1b trials expected to begin mid-2026. The data provide early human biodistribution and tumor uptake insights across solid tumors, supporting clinical development.
Key Facts
- AKY-2519 imaging and dosimetry data will be presented at ASCO 2026 in two poster sessions on May 30.
- FDA cleared IND applications in March 2026 for both imaging ([64Cu]Cu-AKY-2519) and therapeutic ([225Ac]Ac-AKY-2519) use.
- Phase 1b clinical trial for AKY-2519 is expected to start mid-2026.
- Data come from first-in-human PET/CT and SPECT/CT imaging in patients with mCRPC and other solid tumors.
- AKY-2519 is the second clinical-stage candidate from Aktis’ miniprotein radioconjugate platform.
Financial Impact
No direct financial impact disclosed; development-stage update
Risk Factors
- Clinical development risk: Phase 1b trials have not yet started; safety and efficacy remain unproven.
- Forward-looking statements are subject to regulatory, funding, and development uncertainties.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278532 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 6w ago | Institutional Cluster | $24.72 $22.41 | ▼ −9.34% | ▼ −7.37% | $18.11 (−26.74%) |
Jul 10, 2026 12w ago | Insider Cluster | $27.88 $24.13 | ▼ −13.45% | ▼ −15.88% | $18.11 (−35.04%) |
May 21, 2026 19w ago | Press Release | $20.34 $24.48 | ▲ +20.35% | ▲ +21.77% | $18.11 (−10.96%) |
May 11, 2026 20w ago | 8-K | $19.73 $18.58 | ▼ −5.83% | ▼ −4.10% | $18.11 (−8.21%) |
Apr 21, 2026 23w ago | Press Release | $22.00 $18.50 | ▼ −15.91% | ▼ −19.07% | $18.11 (−17.68%) |
Mar 30, 2026 26w ago | Press Release | $17.89 $18.87 | ▲ +5.48% | ▼ −3.94% | $18.11 (+1.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access